Li Tao1, Xu Xiaodong2, Liu Fan3, Dong Gang3, Duan Jun4. 1. Surgery Intensive Care Unit, China-Japan Friendship Hospital, Beijing, China. 2. Department of Orthopedic Surgery, China-Japan Friendship Hospital, Beijing, China. 3. Department of Cardiology, China-Japan Friendship Hospital, Beijing, China. 4. Surgery Intensive Care Unit, China-Japan Friendship Hospital, Beijing, China. junjununun@163.com.
Abstract
BACKGROUND: The purpose of this study is to determine whether new-onset postoperative atrial fibrillation (NOPAF) among patients after hip arthroplasty can predict 1-year mortality. METHODS: All patients over 65 years who underwent hip arthroplasty from January 2013 to December 2017 in a Chinese tertiary hospital were retrospectively analyzed. Patients with paroxysmal and persistent atrial fibrillation were ruled out. 2438 patients were identified to be eligible. The primary endpoint was 1-year mortality after the arthroplasty. RESULTS: Among the 2438 patients, 101 (4.1%) had NOPAF and 2337 (95.9%) had not. Only the current use of beta blocker could predict the occurrence of NOPAF after hip arthroplasty. 1-year mortality for patients with NOPAF was significantly higher than that for patients without NOPAF (70.3% vs 19.0%; p < 0.001). Anti-arrhythmic and anticoagulant treatments were related to 1-year mortality, respectively. With multivariate analysis, NOPA was the most significant variable related to 1-year mortality (hazard ratio 7.8, 95% CI 2.9-24.6). CONCLUSIONS: Among elderly patients after hip arthroplasty, 1-year mortality is increased significantly for patients with NOPAF.
BACKGROUND: The purpose of this study is to determine whether new-onset postoperative atrial fibrillation (NOPAF) among patients after hip arthroplasty can predict 1-year mortality. METHODS: All patients over 65 years who underwent hip arthroplasty from January 2013 to December 2017 in a Chinese tertiary hospital were retrospectively analyzed. Patients with paroxysmal and persistent atrial fibrillation were ruled out. 2438 patients were identified to be eligible. The primary endpoint was 1-year mortality after the arthroplasty. RESULTS: Among the 2438 patients, 101 (4.1%) had NOPAF and 2337 (95.9%) had not. Only the current use of beta blocker could predict the occurrence of NOPAF after hip arthroplasty. 1-year mortality for patients with NOPAF was significantly higher than that for patients without NOPAF (70.3% vs 19.0%; p < 0.001). Anti-arrhythmic and anticoagulant treatments were related to 1-year mortality, respectively. With multivariate analysis, NOPA was the most significant variable related to 1-year mortality (hazard ratio 7.8, 95% CI 2.9-24.6). CONCLUSIONS: Among elderly patients after hip arthroplasty, 1-year mortality is increased significantly for patients with NOPAF.
Entities:
Keywords:
Elderly; Hip arthroplasty; Mortality; Postoperative atrial fibrillation
Authors: Jessica T Huynh; Jeff S Healey; Kevin J Um; Maria E Vadakken; Anand S Rai; David Conen; Pascal Meyre; Jawad H Butt; Hooman Kamel; Seleman J Reza; Stephanie T Nguyen; Zardasht Oqab; P J Devereaux; Kumar Balasubramanian; Alexander P Benz; Emilie P Belley-Cote; William F McIntyre Journal: CJC Open Date: 2021-01-12
Authors: John C Bonano; Ashley K Aratani; Tanmaya D Sambare; Stuart B Goodman; James I Huddleston; William J Maloney; David R Burk; Alistair J Aaronson; Andrea K Finlay; Derek F Amanatullah Journal: J Arthroplasty Date: 2021-05-25 Impact factor: 4.757